A recombinant collagen fragment, its preparation process, and its application in the preparation of topical skincare products.
By incorporating recombinant collagen fragments and utilizing the hydrophobic domains of the mate tag to assist collagen transdermal absorption, the problem of collagen's inability to penetrate the stratum corneum of the skin is solved, achieving effective biological activity and natural collagen synthesis.
Patent Information
- Application Number
- CN202611405754.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-10
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies are unable to effectively penetrate the stratum corneum of the skin, making it difficult for collagen to generate biological signals with living cells and thus unable to exert its biological activity. Furthermore, commonly used methods such as nanovesicle carriers and chemical penetration enhancers have issues with low efficiency or safety.
By designing recombinant collagen fragments, incorporating the chaperone tag of human huntingtin K and a fragment of the core functional region of collagen, and utilizing its hydrophobic domains, transdermal stimulation of dermal cells to synthesize natural collagen can be achieved without relying on other auxiliary methods.
It enables collagen fragments to effectively penetrate the skin without relying on carriers or chemical penetration enhancers, stimulating dermal cells to synthesize natural collagen and improving biological activity and efficiency.
Smart Images

Figure CN123106923A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, specifically relating to a recombinant collagen fragment, its preparation process, and its application in the preparation of topical skincare products. Background Technology
[0002] Collagen is a core component for maintaining skin elasticity and firmness. As we age, the body naturally loses collagen, leading to problems such as sagging skin and deepening wrinkles. Scientifically supplementing collagen or stimulating its regeneration is an important approach to improving skin condition.
[0003] However, under a healthy and intact stratum corneum, large-molecule collagen has great difficulty penetrating. Only trace amounts of molecules can penetrate into the superficial layer of the stratum corneum through appendages such as hair follicles and sweat glands. Most of them remain on the surface of the stratum corneum, where they can only play a moisturizing and film-forming role. They cannot generate biological signals with living cells or exert their biological activity.
[0004] Currently, methods to promote collagen penetration through the epidermis mainly fall into four categories: nanocarrier delivery, chemical permeation enhancement, physical permeation enhancement, and bioengineering. Among these, nanovesicle carriers are the most commonly used approach in topical cosmetics. They rely on biomimetic lipid structures to carry large collagen molecules through the stratum corneum interstitial space and maintain their triple helix conformation under suitable formulation conditions. However, under healthy and intact stratum corneum conditions, most only reach the stratum spinosum / basal layer of the epidermis, with a very low percentage of stable penetration into the dermis. Chemical permeation enhancers are mostly used as auxiliary methods, and potent permeation-enhancing components can easily cause collagen denaturation and inactivation. Physical permeation enhancement methods such as microneedling and ultrasound delivery have the highest penetration efficiency, but they rely on external instruments and are mostly used in medical aesthetic settings. Using genetic engineering to fuse transmembrane peptides and construct short-fragment triple helix recombinant collagen represents a cutting-edge direction that improves transdermal capabilities at the molecular level without relying on delivery carriers. Summary of the Invention
[0005] The purpose of this invention is to provide a recombinant collagen fragment, its preparation process, and its application in the preparation of topical skin care products. This recombinant collagen fragment can effectively penetrate the skin and exert good biological activity.
[0006] To achieve the above-mentioned objectives, the technical solution of the present invention is as follows:
[0007] The present invention first provides a recombinant collagen fragment, which includes a collagen core functional region fragment and a chaperone tag fused to the N-terminus of the collagen core functional region fragment, the amino acid sequence of which is shown in SEQ ID No. 1.
[0008] This invention extracts a fragment from the interacting protein K of human huntingtin and optimizes it through point mutation as a chaperone tag. After fusing this chaperone tag with a collagen core functional region fragment, it was found that the chaperone tag not only enables the soluble expression of the collagen core functional region fragment, but its unique hydrophobic domain can also assist the collagen core functional region fragment to transdermal expression without relying on other auxiliary means (such as delivery carriers, chemical permeation enhancers, or physical permeation enhancers). This allows the collagen core functional region fragment to exert its biological activity and stimulate dermal cells to synthesize natural collagen.
[0009] Preferably, the amino acid sequence of the collagen core functional region fragment is shown in SEQ ID No. 2 or SEQ ID No. 9. This invention optimized the collagen core functional sequence shown in SEQ ID No. 2 by point mutation to obtain SEQ ID No. 9, and the biological activity of the optimized collagen core functional region fragment was significantly improved.
[0010] As a further preferred embodiment, the amino acid sequence of the recombinant collagen fragment is shown in SEQ ID No. 3 or SEQ ID No. 10. In this recombinant collagen fragment, a 6×His tag is also fused to the C-terminus of the collagen core functional region to aid in purification.
[0011] The present invention also provides the encoding gene of the above-mentioned recombinant collagen fragment.
[0012] The present invention also provides a nucleic acid construct containing the above-mentioned coding gene.
[0013] The present invention also provides a recombinant expression vector containing the above-mentioned nucleic acid construct.
[0014] The present invention also provides a genetically modified engineered bacterium containing the above-mentioned encoding gene.
[0015] This invention also provides a preparation process for the above-mentioned recombinant collagen fragment, which includes the following steps:
[0016] S1. Inoculate the above-mentioned genetically modified engineered bacteria into the culture medium and induce fermentation;
[0017] S2. Collect and break the fermentation cells to obtain the whole cell lysate. Centrifuge to obtain the supernatant. Separate and purify the recombinant collagen fragment from the supernatant.
[0018] The recombinant collagen fragment of the present invention can accumulate in Escherichia coli cells and achieve soluble expression, thus making the preparation simpler and meeting the industrial demand for large-scale, low-cost production.
[0019] Preferably, in step S2, the supernatant is subjected to Ni-NTA affinity chromatography and ion exchange chromatography in sequence to obtain a chromatographic solution. The chromatographic solution is then concentrated by ultrafiltration, filtered through a 0.22 μm membrane for sterilization, and dried to obtain the recombinant collagen fragment.
[0020] This invention also provides the application of the above-mentioned recombinant collagen fragments in the preparation of topical skin care products. When this topical skin care product is simply applied to the skin, the recombinant collagen fragments can penetrate the stratum corneum, enter the epidermis, bind to integrins on living cells, and thereby initiate signal transduction, stimulating cells to synthesize natural collagen.
[0021] Compared with the prior art, the beneficial effects of the present invention are reflected in:
[0022] 1. This invention extracts a fragment from the interacting protein K of human huntingtin as a chaperone tag. After fusing this chaperone tag with the collagen core functional region fragment, it was found that the chaperone tag can not only achieve soluble expression of the collagen core functional region fragment, but its unique hydrophobic domain can also assist the collagen core functional region fragment to transdermal expression without relying on other auxiliary means (such as delivery carriers, chemical permeation enhancers, and physical permeation enhancers), so that the collagen core functional region fragment can exert its biological activity and stimulate dermal cells to synthesize natural collagen.
[0023] 2. This invention optimizes the core functional sequence of collagen through point mutation, and the biological activity of the optimized collagen core functional region fragment is significantly improved. Attached Figure Description
[0024] Figure 1 The results show the amino acid sequence alignment of the collagen core functional region segment before and after mutation.
[0025] Figure 2 The agarose gel electrophoresis results of the gene encoding the recombinant collagen fragment of the present invention;
[0026] Figure 3 Agarose gel electrophoresis results for the pET28a plasmid backbone;
[0027] Figure 4 The results were validated by agarose gel electrophoresis of the linearized fragments encoding the gene and the pET28a plasmid backbone.
[0028] Figure 5 This is a schematic diagram of the structure of the recombinant plasmid pET28a-ESC0013;
[0029] Figure 6 The results of SDS-PAGE analysis of the recombinant collagen fragments;
[0030] Figure 7 Comparison of collagen core functional region fragment yields in engineered bacteria before and after adding the mate tag;
[0031] Figure 8 The effect of recombinant collagen fragments on the proliferative capacity of immortalized keratinocytes in HaCat humans;
[0032] Figure 9 Results of the effect of recombinant collagen fragments on the adhesion ability of HFF human foreskin fibroblasts;
[0033] Figure 10 Results 2: Effect of recombinant collagen fragments on the adhesion ability of HFF human foreskin fibroblasts;
[0034] Figure 11 To investigate the effect of recombinant collagen fragments on the migration and repair capacity of immortalized keratinocytes in HaCat humans. Detailed Implementation
[0035] The technical solution of the present invention will be further described in detail below with reference to the accompanying drawings and embodiments.
[0036] Example 1 Construction of genetically modified engineered bacteria
[0037] 1. Filter partner tags
[0038] A fragment was extracted from the interacting protein K of human huntingtin and, after point mutation, was used as a chaperone tag. Its amino acid sequence is as follows:
[0039] MSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLMEAFAKRQGKEMDSLRFLYDGIRIQADQAPEDLDMEDNDIIEAHREQIGG (SEQ ID No. 1).
[0040] 2. Mutations in the core functional region of collagen
[0041] This embodiment uses a core functional region fragment of human type III collagen as a basis for point mutation. The sequence alignment before and after the mutation is as follows: Figure 1 As shown.
[0042] The amino acid sequence of the core functional region fragment of natural human type III collagen (i.e., before mutation) is: GRPGERGLPGPPGIKGPAGIPGFPGEKGHRGDFGRNGEKGETGAPGLKGENGLPGENGAPGPMGPRGAPGERGRPGLP (SEQ ID No. 9).
[0043] The amino acid sequence of the collagen core functional region fragment obtained after mutation is as follows:
[0044] GRPGERGDPGPPGIKGPAGIPGFPGEKGHRGDFGRNGEKGETGAPGLKGENGLPGENGAPGPMGPRGDPGERGRPGLP (SEQ ID No. 2).
[0045] 3. Amino acid sequence design of recombinant collagen fragments
[0046] The amino acid sequence of the recombinant collagen fragment ESC0013 in this embodiment was obtained by designing "partner tag + collagen core functional region fragment (after mutation) + 6×His tag":
[0047] MSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLMEAFAKRQGKEMDSLRFLYDGIRIQADQAPEDLDMEDNDIIEAHREQIGGGRPGERGDPGPPGIKGPAGIPGFPGEKGHRGDFGRNGEKGETGAPGLKGENGLPGENGAPGPMGPRGDPGERGRPGLPHHHHHH (SEQ ID No. 3).
[0048] The amino acid sequence of the recombinant collagen fragment ESC0012 in this embodiment was obtained by designing "partner tag + collagen core functional region fragment (before mutation) + 6×His tag":
[0049] MSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLMEAFAKRQGKEMDSLRFLYDGIRIQADQAPEDLDMEDNDIIEAHREQIGGGRPGERGLPGPPGIKGPAGIPGFPGEKGHRGDFGRNGEKGETGAPGLKGENGLPGENGAPGPMGPRGAPGERGRPGLP HHHHHH (SEQ ID No. 10).
[0050] 4. Gene synthesis
[0051] Based on the E. coli codon preference table, codon optimization was performed on the coding genes of mate tags and collagen core functional region fragments to obtain the coding genes.
[0052] The nucleotide sequence of the gene encoding the recombinant collagen fragment ESC0013 shown in SEQ ID No. 3 is (5'-3'):
[0053] ATGAGCGATAGCGAAGTGAACCAGGAAGCGAAACCGGAAGTGAAACCGGAAGTAAAACCGGAAACCCA CATTAACCTGAAAGTGAGCGATGGCAGCAGCGAAATTTTTTTTAAAATTAAAAAAACCACCCCGCTGCGTCGTCTG ATGGAAGCCTTCGCGAAACGTCAGGGCAAAGAAATGGATAGCCTGCGCTTTCTGTATGATGGCATTCGTATTCAGG CAGATCAGGCGCCGGAAGATCTGGATATGGAAGATAACGATATTATTGAAGCCCATCGCGAACAGATTGGCGGCgg tcgtccgggagaacgcggcgacccgggtccgccgggtatcaaaggtccggctggtatcccgggtttcccgggtgaa aaaggtcaccgtggtgacttcggtcgtaacggtgaaaaaggtgaaaccggtgctccgggtctgaaaggtgaaaacg gtctgccgggtgaaaacggtgctccgggtccgatgggtccgcgtggtgacccgggtgaacgtggtcgtccgggtct gccg caccaccaccaccaccac (SEQ ID No. 4).
[0054] The nucleotide sequence of the gene encoding the recombinant collagen fragment ESC0012 shown in SEQ ID No. 10 is (5'-3'):
[0055] ATGAGCGATAGCGAAGTGAACCAGGAAGCGAAACCGGAAGTGAAACCGGAAGTAAAACCGGAAACCCA CATTAACCTGAAAGTGAGCGATGGCAGCAGCGAAATTTTTTTTAAAATTAAAAAAACCACCCCGCTGCGTCGTCTG ATGGAAGCCTTCGCGAAACGTCAGGGCAAAGAAATGGATAGCCTGCGCTTTCTGTATGATGGCATTCGTATTCAGG CAGATCAGGCGCCGGAAGATCTGGATATGGAAGATAACGATATTATTGAAGCCCATCGCGAACAGATTGGCGGCgg tcgtccgggagaacgcggcgacccgggtccgccgggtatcaaaggtccggctggtatcccgggtttcccgggtgaa aaaggtcaccgtggtgacttcggtcgtaacggtgaaaaaggtgaaaccggtgctccgggtctgaaaggtgaaaacg gtctgccgggtgaaaacggtgctccgggtccgatgggtccgcgtggtgacccgggtgaacgtggtcgtccgggtct gccg caccaccaccaccaccac (SEQ ID No. 11).
[0056] Since the pET28a plasmid backbone carries a 6×His tag, in this embodiment only the underlined part of the coding gene was synthesized by Platinum Biotech (Shanghai) Co., Ltd.
[0057] 5. Construction of recombinant expression vectors
[0058] (1) Encoding gene amplification
[0059] Using a synthetically produced coding gene fragment (SEQ ID No. 4) as a template, PCR amplification was performed using specific primers:
[0060] ESC0013-Expression Box-F: 5'-CTTTAAGAAGGAGATATACCaATGAGCGATAGCGAAGTGAACCAGG-3' (SEQ ID No. 5);
[0061] ESC0013-Expression cassette-R: 5'-TGTTAGTGGTGGTGGTGGTGGTGCGGCAGACCCGG-3' (SEQ ID No. 6).
[0062] The amplification system is shown in Table 1. It was prepared in 50 µL of reaction system according to Section IV "PCR Reaction Composition" of Takara PrimeSTAR Max DNA Polymerase (Cat. #R045A, manual version V202102Da).
[0063] Table 1
[0064] reagents Dosage Final concentration PrimeSTAR Max Premix (2×) (contains 2 mM Mg²⁺ + 0.4 mM each dNTP) 25 µL 1× ESC0013-Expression Frame-F (10 µM) 1µL 0.5µM ESC0013-Expression Frame-R (10 µM) 1µL 0.5µM Template DNA 50 ng — Sterilized purified water Topping up to 50 µL —
[0065] After the PCR reaction solution was prepared on ice, it was transferred to the PCR instrument and amplified according to the 3-step PCR cycling conditions recommended in Section V of the R045A instruction manual, PCR Conditions (A) (see Table 2).
[0066] Table 2
[0067] step temperature time Cycle number transsexual 98 ℃ 10 sec 30 cycles annealing 55 ℃ 5 sec 30 cycles extend 72 ℃ 5 sec / kb 30 cycles
[0068] After the reaction, take 5 µL of product + 1 µL of 6× DNA Loading Dye for 1% agarose gel electrophoresis. The product size should be approximately 700 bp.
[0069] 1% agarose gel electrophoresis showed a specific band of approximately 550 bp (see [link]). Figure 2 The fragment size was consistent with the expected size, with no nonspecific amplification; it could proceed to the downstream Dpn I enzyme digestion and template removal step.
[0070] (2) pET28a plasmid backbone amplification
[0071] Using DNA containing the C-terminal human type III collagen coding sequence and the pET28a plasmid backbone (containing a 6×His tag sequence) as a template, PCR amplification was performed using specific primers:
[0072] ESC0013-Backbone-F: 5'-GTGACCGTGGTGACACCGGTCACCACCACCACC ACCACTAACAAAGC-3' (SEQ ID No. 7);
[0073] ESC0013-Skeleton-R: 5'-GGTATATCTCCTTCTTAAAGTTAAACAAAATTATT TCTAGAGGGG-3' (SEQ ID No. 8).
[0074] The PCR reaction system is the same as in Table 1; the PCR reaction procedure is the same as in Table 2.
[0075] After the reaction, take 5 µL of product + 1 µL of 6× DNA Loading Dye for 1% agarose gel electrophoresis. The product size should be approximately 5200 bp.
[0076] 1% agarose gel electrophoresis showed a specific band of approximately 5200 bp (see [link]). Figure 3 The fragment size was consistent with the expected size, with no nonspecific amplification; it could proceed to the downstream Dpn I enzyme digestion and template removal step.
[0077] (3) Processing of amplification products (Dpn I enzyme digestion to remove template)
[0078] The PCR products obtained in steps (1) and (2) were diluted to 50 µL with sterile water, and the enzyme digestion reaction solution was prepared in 20 µL of the reaction system according to the "General Reaction System" of Takara Dpn I (Cat. #1235A, instruction manual V201808Da) (see Table 3 below).
[0079] Table 3
[0080] reagents Dosage Dpn I (10 U / µL) 1 µL 10× T Buffer 2 µL DNA ≤1 µg Sterilized water Topping up to 20 µL
[0081] After gently mixing, briefly centrifuge and incubate at 37 ℃ in a water bath or PCR instrument for 1 h (the instructions define one unit of activity (U) as the amount of enzyme required to completely degrade 1 µg of adenine methylated pBR322 DNA in 50 µL of reaction solution at 37 ℃ for 1 h). After the reaction, inactivate the enzyme by heat treatment at 70 ℃ for 15 min according to the "inactivation conditions" in the instructions before proceeding to the downstream PCR product purification step.
[0082] (4) Purification of enzyme digestion products
[0083] Using the SanPrep column PCR product purification kit (Cat. #B518131 / B518141, manual version 6.0), the enzyme digestion product obtained in step (3) was purified according to its "standard purification procedure". The specific steps are as follows:
[0084] 1) Add 5 volumes of Buffer B3 to every 100 µL of enzyme digestion product, mix well, transfer to an adsorption column, and centrifuge at 8,000×g for 30 sec.
[0085] 2) Add 500 µL Wash Solution (containing anhydrous ethanol), centrifuge at 9,000×g for 30 sec;
[0086] 3) Repeat step 2) once; centrifuge the empty column at 9,000 × g for 1 min;
[0087] 4) Transfer the adsorption column to a new 1.5 mL centrifuge tube, add 30–50 µL of Elution Buffer to the center of the adsorption membrane, let stand at room temperature for 1 min, then centrifuge at 9,000×g for 1 min to collect the purified product.
[0088] Figure 4 The results showed that two high-purity linear DNA fragments (fragment 1 approximately 550 bp and fragment 2 approximately 5200 bp) were obtained, with OD260 / 280 ratios between 1.8 and 2.0, which can be directly used for downstream seamless cloning assembly.
[0089] (5) Seamless cloning assembly
[0090] First, the concentration of the purified fragment was detected using nanodrop. After obtaining the concentration, a 20 µL reaction system was prepared using the Shanghai Sangon Biotech Ready-to-Use Seamless Cloning Kit (Cat. #B632219, specification 20 / 40 times) according to the procedure in Section 4 "Recombination of Target Fragment and Vector" (see Table 4).
[0091] Table 4
[0092] Components Dosage 2× Seamless Cloning Master Mix 10 µL Linearized vector pET28a The molar ratio of the inserted fragment to the inserted fragment is 1:3. Insertion fragment (i.e., the enzyme digestion product obtained in step (4)) Total moles : Carrier = 3 : 1 <![CDATA[Sterilized ddH2O]]> Topping up to 20 µL
[0093] After gently tapping to mix, briefly centrifuge and incubate at 50°C for 50 min in a PCR instrument or water bath. Immediately after the reaction, place the centrifuge tube on ice to cool for 2 min before transformation.
[0094] (6) Transformation of competent cells
[0095] The assembled product was used to transform DH5α competent cells according to the "Usage Method" procedure in the product instructions of Daling Biotechnology DL-DH5α Chemical Transformation Competent Cells (Cat. #DLC114); the specific steps are as follows:
[0096] 1) Take 100 µL of Daling Bio DL-DH5α competent cells (Cat. #DLC114) thawed on ice into a 1.5 mL centrifuge tube, add the assembly product obtained in step (5) (add the target DNA as required by the instructions), mix gently, and let stand on ice for 30 min;
[0097] 2) Heat shock in a 42 ℃ water bath for 45–90 sec, then quickly transfer to an ice bath and let stand for 2 min (do not shake the sample during the standing on ice, otherwise it will reduce the conversion efficiency).
[0098] 3) Add 700 µL of antibiotic-free sterile liquid culture medium (SOB or LB) to the centrifuge tube, mix well, and incubate at 37 ℃ and 200 rpm for 60 min.
[0099] 4) Spread the resuscitation solution evenly onto an SOB or LB medium plate containing 50 µg / mL kanamycin sulfate, and invert the plate to incubate overnight at 37 ℃.
[0100] 5) Select single colonies with good morphology that have grown on the plate, and verify them by colony PCR and Sanger sequencing (completed by Sangon Biotech) to confirm that the recombinant plasmid pET28a-ESC0012 sequence is completely correct, without frameshift or mutation.
[0101] (7) Extraction of recombinant plasmids
[0102] Select the single colonies that have been correctly sequenced in step (6) and inoculate them into 5 mL of LB liquid medium containing 50 µg / mL kanamycin sulfate. Incubate at 37 ℃ with shaking (220 rpm) for 16 h (the volume of the bacterial culture should not exceed 1 / 4 of the container capacity). Use the SanPrep column-based plasmid DNA mini-extraction kit (Cat. #B518191, version 6.0 of the instruction manual) and follow the "Standard Extraction Procedure". The specific steps are as follows:
[0103] 1) Take 2 mL of bacterial culture, centrifuge at 8,000×g for 2 min to collect the bacterial cells, and discard the culture medium;
[0104] 2) Add 250 µL Buffer P1 (containing RNase A) to thoroughly suspend the bacterial cells;
[0105] 3) Add 250 µL of Buffer P2, immediately and gently invert the centrifuge tube 10 times to mix, and let stand at room temperature for 2 minutes;
[0106] 4) Add 350 µL Buffer P3, and immediately gently invert the centrifuge tube 10 times to mix thoroughly. A large amount of white flocculent precipitate will be visible.
[0107] 5) Centrifuge at 12,000×g for 10 min, transfer the supernatant into the adsorption column, centrifuge at 8,000×g for 30 sec, and discard the liquid in the collection tube;
[0108] 6) Add 500 µL Buffer DW1, centrifuge at 9,000×g for 30 sec, and discard the liquid in the collection tube;
[0109] 7) Add 500 µL Wash Solution (containing anhydrous ethanol), centrifuge at 9,000×g for 30 sec, discard the liquid in the collection tube, and repeat once;
[0110] 8) Centrifuge the empty adsorption column at 9,000 × g for 1 min;
[0111] 9) Place the adsorption column into a clean 1.5 mL centrifuge tube, add 50 µL of Elution Buffer to the center of the adsorption membrane, let stand at room temperature for 1 min, then centrifuge for 1 min to collect plasmid DNA.
[0112] The final high-copy recombinant plasmid pET28a-ESC0013 was obtained, with an OD260 / 280 ratio between 1.8 and 1.9, and an OD260 / 230 ratio greater than 2.0. More than 20 µg of plasmid DNA was obtained from 5 mL of overnight bacterial culture, which can be directly used for the construction of downstream BL21(DE3) expression strains. A schematic diagram of the recombinant plasmid pET28a-ESC0013 is shown below. Figure 5 As shown.
[0113] (8) Constructing genetically modified bacteria
[0114] The recombinant plasmid pET28a-ESC0013 obtained in step (7) was transformed into the BL21(DE3) host strain according to the procedure of Daling Biotechnology DL-BL21(DE3) chemical transformation competent cells (Cat. #DLC201, product manual "Instructions for Use" section). The genotype of this host strain is F-ompT hsdS B (rB mB) gal dcm (DE3), and the chromosome integrates the T7 RNA polymerase gene of the phage DE3 region that can be expressed by the lacUV5 promoter; it is suitable for high-efficiency expression in T7 promoter expression vectors (such as pET28a, pGEX4T-2); the transformation efficiency detected by pUC19 plasmid DNA can reach 1×10 8 cfu / µg; expression efficiency was 20% higher than that of similar strains. The specific construction steps are as follows:
[0115] 1) Take 100 µL of Daling Bio DL-BL21(DE3) competent cells (Cat. #DLC201) thawed on ice into a 1.5 mL centrifuge tube, add the recombinant plasmid pET28a-ESC0013 extracted in step 7 (recommended addition amount 10 pg–100 ng), mix gently, and let stand on ice for 30 min;
[0116] 2) Heat shock in a 42 ℃ water bath for 45–90 sec, then quickly transfer to an ice bath and let stand for 2 min (do not shake the sample during the standing on ice, otherwise it will reduce the conversion efficiency).
[0117] 3) Add 700 µL of antibiotic-free sterile liquid culture medium (SOB or LB) to the centrifuge tube and incubate at 37 °C and 200 rpm for 60 min;
[0118] 4) Spread the resuscitation solution evenly onto an SOB or LB plate containing 50 µg / mL kanamycin sulfate, and invert the plate to incubate overnight at 37 ℃.
[0119] 5) Take 100 µL of Daling Bio DL-BL21(DE3) competent cells (Cat. #DLC201) + 1 µL of the matching pUC19 control plasmid (10 pg / µL) and transform them according to the same procedure as above, as a positive control for transformation efficiency.
[0120] Single colonies with good morphology were picked from the plates; colony PCR verification (using pET28a universal primers T7 / T7-ter) confirmed that the recombinant plasmid had been successfully transformed into the BL21(DE3) expression host; at the same time, a large number of colonies grew on the pUC19 control plate, and the transformation efficiency met the requirement of ≥ 1×10⁻⁶. 8 The product quality control standard of cfu / µg can be used for subsequent shake-flask fermentation verification.
[0121] Genetically engineered bacteria integrating the gene encoding SEQ ID No. 11 were also constructed using the same method described above, and will not be elaborated further.
[0122] Example 2: Preparation and performance analysis of recombinant collagen fragments
[0123] 1. Preparation of recombinant collagen fragments
[0124] Single colonies of the genetically modified engineered bacteria constructed in Example 1 were inoculated into 5 mL LB broth containing 50 µg / mL kanamycin sulfate in a test tube and cultured overnight at 37 °C with shaking (220 rpm). The culture was then transferred at 1–4% inoculation volume to LB broth conical flasks containing 50 µg / mL kanamycin sulfate (LB volume not exceeding 1 / 5 of the maximum volume indicated on the conical flask), and cultured at 37 °C with shaking (220 rpm) until OD600 = 0.8. Following the instructions for the Daling Bio DL-BL21(DE3) product, "Precautions" section 4 (IPTG is required when the T7 promoter expression vector contains the lacI gene; concentrations of 0.1–2 mM are acceptable), IPTG was added to a final concentration of 0.1 mM, and induction continued at 34 °C for 4 h. 20 µL of the bacterial culture was then added to 5 µL of 5× protein electrophoresis loading buffer, and lysed at 98 °C for 10 min. 2–3 µL of the lysate was then collected. Load the sample and perform 15% SDS-PAGE protein gel electrophoresis analysis.
[0125] Figure 6 SDS-PAGE analysis showed that the target band area accounted for more than 1 / 3 of the total band area, indicating that the target protein was significantly enriched in the soluble supernatant and had extremely high intracellular solubility, eliminating the need for inclusion body renaturation. Cells were collected by centrifugation, weighed, and resuspended in equilibration buffer (formulation: 50 mM PB, 250 mM NaCl, pH=7.4). Cells were homogenized at 800 bar using a high-pressure homogenizer, cyclically twice, to obtain lysis buffer. The lysis buffer was centrifuged at 4°C and 8000 rpm for 45 min, and the supernatant was collected. The supernatant was filtered through a 0.2 μm hollow fiber microfilter to obtain permeate with a turbidity of less than 30 NTU, which was used as the sample for chromatography loading. The sample was loaded into a Ni-NTA affinity chromatography column pre-equilibrated with equilibration buffer at a flow rate of 76 cm / h. Contaminating proteins were removed with elution buffer containing 30 mM imidazole, followed by elution with elution buffer containing 200 mM imidazole. To further reduce endotoxin levels, the protein solution was loaded onto a Q Sepharose Fast Flow anion exchange chromatography column, and the flow-through was collected. The endotoxin-free sample was concentrated using 10 kDa hollow fiber ultrafiltration, and the buffer was pre-replaced with 3 mM PB at pH 7.4. Finally, the sample was filtered through a 0.22 μm sterile membrane and freeze-dried under vacuum to obtain the recombinant collagen fragments ESC0012 and ESC0013 of this embodiment.
[0126] Using genetically engineered bacteria integrating the collagen core fragment shown in SEQ ID No. 2 (i.e., without the tag) as a comparison, the yield of recombinant collagen fragment ESC0013 in the genetically engineered bacteria was tested, and the results are as follows: Figure 7 As shown.
[0127] from Figure 7 It can be seen that the yield of recombinant collagen fragment ESC0013 was significantly increased after the addition of the chaperone tag, indicating that the chaperone tag can improve the soluble expression ratio of collagen core functional region fragments.
[0128] 2. Performance analysis of recombinant collagen fragments
[0129] (1) Cell proliferation assay
[0130] HaCat immortalized keratinocytes were seeded in 96-well plates and cultured at 37°C with 5% CO2 for 24 hours. The cells were then divided into groups, and each group was treated as follows: 1) Blank control group (basal medium); 2) Solvent control group (cells + basal medium); 3) Sample group ① (cells + 0.1 mg / ml ESC0012 + basal medium); 4) Sample group ② (cells + 0.1 mg / ml mutant collagen core functional region fragment + basal medium); 5) Sample group ③ (cells + 0.1 mg / ml ESC0013 + basal medium); 6) Experimental group ④ (cells + 0.1 mg / ml natural human type III collagen core functional region fragment + basal medium); 7) Experimental group ⑤ (cells + 0.1 mg / ml commercially available collagen (humanized recombinant type III collagen S100-01) + basal medium). After treatment, the cells were cultured for another 1.5 hours. CCK-8 reagent was added at 24, 48, and 72 hours, and the cells were then incubated at 37°C for 1.5 hours. The absorbance at 450 nm was then measured using a microplate reader, and the relative cell proliferation rate was calculated using the following formula:
[0131] Relative cell proliferation rate % = 100 * (OD sample group - OD blank control group) / (OD solvent control group - OD blank control group).
[0132] Statistical analysis was performed using Prism GraphPad 9.0 software. Results are expressed as Mean ± SD. A p ≤ 0.05 was considered statistically significant, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001.
[0133] The results are as follows Figure 8As shown, compared with collagen core functional region fragments and commercially available collagen, recombinant collagen fragments ESC0012 and ESC0013 have a more significant effect on inducing cell proliferation.
[0134] (2) Cell adhesion test
[0135] The collagen core functional region fragments before and after mutation, commercially available collagen, bovine collagen, and recombinant collagen fragments ESC0012 and ESC0013 were added to untreated 96-well plates at a final concentration of 0.1 mg / ml. The plates were incubated at 37°C and 5% CO2 for 2 hours, then discarded. The plates were washed with PBS, and then blocked with 1% BSA solution for 1 hour. After blocking, the blocking solution was discarded, and the plates were washed with PBS. HFF human foreskin fibroblasts were added, with PBS-coated cells serving as a blank control group. The plates were cultured for another 2 hours. After incubation, the plates were washed with PBS to remove unattached cells, and then CCK-8 reagent was added. The plates were incubated at 37°C for 1 hour, and the absorbance at 450 nm was measured using a microplate reader. The results are as follows: Figure 8 and Figure 9 As shown.
[0136] from Figure 9 and Figure 10 It can be seen that, compared with the core functional region fragment of natural human type III collagen, commercially available collagen, and bovine serum albumin, recombinant collagen fragments ESC0012 and ESC0013 can significantly enhance cell adhesion.
[0137] (3) Cell scratch test
[0138] Draw three straight lines on the back of the six-hole board using a marker, in a 4×10 pattern. 5 HaCat human keratinocytes were seeded into 6-well plates and cultured at 37°C with 5% CO2 until confluence reached 90%. Three straight lines were drawn perpendicular to the bottom of the well using a 200 μl pipette tip. The culture medium was discarded, and the cells were gently washed three times with PBS to remove the drawn cells. 1 ml of DMEM medium (containing 0.2% serum) was added to each well. The following solutions were added to the corresponding wells: DMEM medium containing 0.2% serum (solvent control group); DMEM medium containing 0.1 mg / ml ESC0012 (containing 0.2% serum); DMEM medium containing 0.1 mg / ml commercially available collagen (humanized recombinant type III collagen S100-01) (containing 0.2% serum); and DMEM medium containing 0.1 mg / ml ESC0013 (containing 0.2% serum). Two replicates were created for each group, and the scratches were photographed at 0 h and 24 h.
[0139] from Figure 11The results showed that, compared with commercially available collagen, recombinant collagen fragments ESC0012 and ESC0013 had a more significant promoting effect on cell scratch healing ability, suggesting that recombinant collagen fragments ESC0012 and ESC0013 have repair potential in vivo.
[0140] Example 3: Application of recombinant collagen fragments in the preparation of topical skin care products
[0141] 1. Emulsion preparation
[0142] The recombinant collagen fragment ESC0012 prepared in Example 2 was added to the emulsion to obtain sample group emulsion ① (final concentration of recombinant collagen fragment was 50 ppm, i.e., 0.005%). The emulsion with added mutated collagen core functional region fragment (i.e., without chaperone tag, amino acid sequence of SEQ ID No. 2) was used as control group emulsion ① (final concentration of 50 ppm). The recombinant collagen fragment ESC0013 prepared in Example 2 was added to the emulsion to obtain sample group emulsion ② (final concentration of 50 ppm). The emulsion with added unmutated collagen core functional region fragment (i.e., without chaperone tag, amino acid sequence of SEQ ID No. 9) was used as control group emulsion ② (final concentration of 50 ppm). The emulsion without any added collagen component was used as blank group emulsion. Except for the collagen, the other components of the emulsions were completely the same.
[0143] 2. Volunteer Recruitment
[0144] A total of 33 volunteer subjects were recruited for this experiment, and 31 of them completed the project; among them, 27 were female and 6 were male; their ages ranged from 30 to 59 years; the mean age was 43.2 ± 8.5 years, with the minimum age being 30 years, the median age being 44 years, and the maximum age being 59 years.
[0145] 3. Usage effect test
[0146] (1) Test method
[0147] Referring to the "T / CAB 012~2022 Test Methods for Seven Efficacy Items of Cosmetics (Anti-wrinkle, Firming, Moisturizing, Oil Control, Repairing, Nourishing, and Soothing)" and the internal methods of the testing institution, the changes in the state of the test sites before and after the subjects used the corresponding products were evaluated to assess the effects of the products on moisturizing, repairing, nourishing, firming, and anti-wrinkle.
[0148] (2) Short-term moisturizing test on the inner forearm
[0149] A test area ①, a control area ①, a test area ②, a control area ②, and a blank area were set up on the flexor side of each forearm of the subject. Each area was 3 cm × 3 cm in size. After measuring the initial values of each test area, (20 ± 0.1) mg / cm² of sample was applied to the corresponding positions on the left and right arms of the subject. Specifically, test area ① was applied with sample group emulsion ①, test area ② with sample group emulsion ②, control area ① with control group emulsion ①, control area ② with control group emulsion ②, and the blank area with blank group emulsion. After application, the subject sat still in a constant temperature and humidity environment (temperature 20–22 ℃, humidity 40–60 %RH). The stratum corneum moisture content of each test area of the subject was measured using a skin test probe (Corneometer CM825) 4 h and 8 h after sample use, and the mean stratum corneum moisture content (mean ± SD, N = 31) was calculated. The results are shown in Table 5.
[0150] Table 5
[0151] area Time point average moisture content of stratum corneum Difference vs. Initial Paired t-test p-value blank area T0 31.58 — — blank area T4 h 31.18 −0.40 0.663 (ns) blank area T8 h 28.90 −1.88 0.059 (ns) Control area ① T0 30.53 — — Control area ① T4 h 43.44 +12.91 <0.001 (***) Control area ① T8 h 41.69 +10.16 <0.001 (***) Experimental Zone ① T0 30.58 — — Experimental Zone ① T4 h 45.08 +14.50 <0.001 (***) Experimental Zone ① T8 h 43.68 +13.10 <0.001 (***) Control area ② T0 29.13 — — Control area ② T4 h 41.44 +12.31 <0.001 (***) Control area ② T8 h 39.69 +10.56 <0.001 (***) Experimental Zone ② T0 30.58 — — Experimental Zone ② T4 h 48.28 +17.70 <0.001 (***) Experimental Zone ② T8 h 46.58 +16.00 <0.001 (***)
[0152] As shown in Table 5, compared with the corresponding control area, the mean stratum corneum moisture content in the experimental area was significantly different at T4 h and T8 h (P = 0.05, P = 0.01); indicating that the recombinant collagen fragment exhibits a superior short-term moisturizing effect compared with the simple collagen core functional area fragment.
[0153] (3) Long-term facial efficacy test
[0154] The subjects' left and right faces were designated as test area ①, control area ①, test area ②, and control area ②, respectively. Sample group emulsions ① and ②, and control group emulsions ① and ② were applied to the left and right faces, respectively. The application method was as follows: use a dropper to draw 4 drops and massage in a clockwise circular motion until absorbed; apply once in the morning and once in the evening. Facial condition was tested after 2 weeks, 4 weeks, and 8 weeks of use.
[0155] 1) Stratum corneum moisture content test
[0156] The stratum corneum moisture content of each test area of the subject was tested using a skin test probe (Corneometer CM825), and the mean stratum corneum moisture content (mean ± SD, N = 31) was calculated. The results are shown in Table 6.
[0157] Table 6
[0158] area initial 2 weeks 4 weeks 8 weeks Control area ① 55.57 56.33 (+1.4%) 54.43 (−2.0%) 54.26 (−2.4%) Experimental Zone ① 54.69 67.72 (+23.9%) 69.15 (+26.4%) 71.26 (+30.3%) Control area ② 52.30 54.32 (+3.9%) 51.38 (−1.8%) 55.26 (+5.7%) Experimental Zone ② 55.30 69.72 (+26.1%) 72.25 (+30.7%) 75.56 (+36.6%)
[0159] As shown in Table 6, compared with the initial values, the mean stratum corneum moisture content in control areas ① and ② showed little or no difference after 2, 4, and 8 weeks of use. However, compared with the initial values, the mean stratum corneum moisture content in experimental areas ① and ② showed significant differences after 2, 4, and 8 weeks of use (P < 0.01). Compared with the corresponding control areas, the mean stratum corneum moisture content in the experimental areas also showed significant differences after 2, 4, and 8 weeks of use (P < 0.01 for all 2 / 4 / 8 weeks). In summary, this indicates that recombinant collagen fragments exhibit superior long-lasting moisturizing effects compared to simple collagen core functional area fragments.
[0160] 2) Transepidermal water loss rate (g / m²h, a key repair parameter)
[0161] The transepidermal water loss rate (mean ± SD, N = 31) of each test area of the subjects was measured using Tewameter™ He, and the results are shown in Table 7.
[0162] Table 7
[0163] area initial 2 weeks 4 weeks 8 weeks Control area ① 28.98 26.20 (−9.6%) 21.58 (−25.5%) 23.52 (−18.8%) Experimental Zone ① 27.89 19.32 (−30.7%) 16.92 (−39.3%) 16.28 (−41.6%) Control area ② 26.73 25.52 (−4.5%) 20.92 (−21.7%) 21.98 (−17.8%) Experimental Zone ② 29.77 21.82 (−26.7%) 19.22 (−35.4%) 18.33 (−38.4%)
[0164] As shown in Table 7, after 2, 4, and 8 weeks of use, the transepidermal water loss rate in both the control and experimental areas was significantly reduced. However, compared with the corresponding control areas, the reduction in transepidermal water loss rate was greater in experimental areas ① and ②, and the differences were statistically significant (P < 0.05 at 2 weeks, P ≤ 0.01 at 4 weeks, and P < 0.01 at 8 weeks). In summary, this indicates that recombinant collagen fragments exhibit superior repair effects compared to collagen core functional area fragments.
[0165] 3) Elasticity R2 (%, key parameters for firming and nourishing)
[0166] The skin elasticity R2 (mean ± SD, N = 31) of each test area of the subjects was measured using a Cutometer dual MPA580, and the results are shown in Table 8.
[0167] Table 8
[0168] area initial 2 weeks 4 weeks 8 weeks Control area ① 61.02 60.51 (−0.8%) 61.07 (+0.0%) 58.55 (−4.0%) Experimental Zone ① 60.09 67.83 (+12.9%) 72.45 (+20.6%) 74.36 (+23.7%) Control area ② 59.12 59.91 (+1.3%) 60.37 (+2.1%) 59.45 (+0.6%) Experimental Zone ② 58.79 65.76 (+11.9%) 71.25 (+21.2%) 75.86 (+29.0%)
[0169] As shown in Table 8, compared with the initial values, there were no significant differences in the mean elasticity R² values of control areas ① and ② after 2, 4, and 8 weeks of use. However, compared with the corresponding control areas, the mean elasticity R² values of each experimental area showed significant differences after 2, 4, and 8 weeks of use (P < 0.01 for all 2 / 4 / 8 weeks). In summary, this indicates that compared with simple collagen core functional area fragments, recombinant collagen fragments exhibit superior firming and nourishing effects.
[0170] 4) Firmness F4 (mm·s, a key parameter for firmness; the lower the value, the firmer the skin)
[0171] The tightness F4 (mean ± SD, N = 31) of each test area of the subjects was tested using a Cutometer dual MPA580, and the results are shown in Table 9.
[0172] Table 9
[0173] area initial 2 weeks 4 weeks 8 weeks Control area ① 1.68 1.94 (+15.5%) 1.71 (+1.8%) 1.76 (+4.8%) Experimental Zone ① 1.64 1.75 (+6.7%) 1.52 (−7.3%) 1.21 (−26.2%) Control area ② 1.61 1.84 (+14.3%) 1.78 (+10.5%) 1.89 (+17.4%) Experimental Zone ② 1.69 1.76 (+4.3%) 1.44 (−14.8%) 1.29 (−23.7%)
[0174] As shown in Table 9, compared with the initial values, the firmness F4 values of control areas ① and ② both showed varying degrees of improvement, indicating that the core functional area fragments of collagen alone could not improve skin firmness. However, the firmness F4 values of experimental areas ① and ② decreased significantly after 4 and 8 weeks of use. Compared with the corresponding control areas, there were significant differences in the firmness F4 values of each experimental area (P < 0.01), indicating that the recombinant collagen fragments have excellent firming effects, and the longer the use time, the higher the skin firmness.
[0175] 5) Gloss (a key parameter for nourishment; the higher the value, the better the gloss)
[0176] The glossiness of each test area of the subjects was tested using a Glossymeter GL200 (mean ± SD, N = 31), and the results are shown in Table 10.
[0177] Table 10
[0178] area initial 2 weeks 4 weeks 8 weeks Control area ① 9.50 9.74 (+2.5%) 9.36 (−1.5%) 9.13 (−3.9%) Experimental Zone ① 9.65 12.41 (+28.6%) 12.50 (+29.5%) 13.03 (+35.0%) Control area ② 9.45 9.66 (+2.2%) 9.71 (+2.8%) 9.28 (−1.8%) Experimental Zone ② 9.53 11.91 (+25.0%) 12.35 (+29.6%) 13.22 (+38.7%)
[0179] As shown in Table 10, compared with the initial values, there were no significant differences in glossiness in control areas ① and ② after 2, 4, and 8 weeks of use. However, compared with the initial values or control areas, the glossiness of experimental areas ① and ② were significantly different after 2, 4, and 8 weeks of use (P<0.01). In summary, this indicates that recombinant collagen fragments exhibit superior nourishing effects compared to simple collagen core functional area fragments.
[0180] 6) Heme content
[0181] The heme content (mean ± SD, N = 31) in each test area of the subjects was measured using the Antera3D skin three-dimensional imaging system. The results are shown in Table 11.
[0182] Table 11
[0183] area initial 2 weeks 4 weeks 8 weeks Control area ① 27.45 26.92 (−1.9%) 26.68 (−2.8%) 26.04 (−5.1%) Experimental Zone ① 30.04 27.10 (−9.8%) 26.14 (−13.0%) 25.74 (−14.3%) Control area ② 26.35 25.82 (−2.0%) 24.98 (−5.2%) 25.24 (−4.2%) Experimental Zone ② 28.14 26.14 (−7.1%) 25.77 (−8.4%) 24.67 (−12.3%)
[0184] As shown in Table 11, compared with the initial values, the heme content in control area ① was significantly different after 2, 4, and 8 weeks of use (P<0.05 for 2 / 4 weeks, P<0.01 for 4 weeks), and the heme content in control area ② was also significantly different (P<0.05 for 2 weeks, P<0.01 for 4 / 8 weeks). Compared with the initial values, the heme content in experimental areas ① and ② was significantly different after 2, 4, and 8 weeks of use (P<0.01). Compared with the control area, the heme content in the experimental areas was also significantly different after 2, 4, and 8 weeks of use (P<0.05 for 2 weeks, P<0.05 for 4 weeks, P<0.01 for 8 weeks), and the longer the use time, the greater the difference. In summary, compared with the core functional area fragment of collagen, the recombinant collagen fragment exhibits superior repair effects, reducing skin redness / inflammation and improving permeability.
[0185] Heme seeps from capillaries into the extracellular matrix, causing skin darkening. However, compared to simple collagen core functional region fragments, recombinant collagen fragments significantly reduced heme content in the extracellular matrix. This suggests that the chaperone tag facilitates the recombinant collagen fragments' penetration through the stratum corneum into the epidermis, promoting collagen synthesis in the extracellular matrix, strengthening the pericapillary tissue structure, and improving heme leakage.
[0186] Based on three parameters—glossiness, stratum corneum moisture content, and heme content—it is shown that ESC0012 can improve skin from dull and reddish to bright and clear.
[0187] 7) Skin roughness Ra (a key parameter for nourishing; the lower the value, the smoother the skin)
[0188] The skin roughness Ra (mean ± SD, N = 31) of each test area of the subjects was tested using the Antera3D skin three-dimensional imaging system. The results are shown in Table 12.
[0189] Table 12
[0190] area initial 2 weeks 4 weeks 8 weeks Control area ① 7.138 6.873 (−3.7%) 6.947 (−2.7%) 6.782 (−5.0%) Experimental Zone ① 7.757 6.747 (−13.0%) 6.358 (−18.0%) 5.725 (−26.2%) Control area ② 7.215 6.985 (−3.2%) 6.884 (−4.6%) 6.913 (−4.2%) Experimental Zone ② 7.344 6.538 (−11.0%) 6.258 (−14.8%) 5.427 (−26.1%)
[0191] As shown in Table 12, compared with the initial value, the roughness of control area ① decreased after 2, 4, and 8 weeks of use, but the difference was not significant. However, compared with the initial value, the roughness of experimental areas ① and ② showed significant differences after 2, 4, and 8 weeks of use (P<0.01). Furthermore, compared with the corresponding control areas, the roughness of each experimental area also showed significant differences after 2, 4, and 8 weeks of use (2 weeks P<0.05, 4 / 8 weeks P<0.01), and the longer the use time, the more obvious the difference. In summary, compared with the collagen core functional area fragment, the recombinant collagen fragment exhibits a superior long-lasting nourishing effect.
[0192] 8) Fine line count (lines, a key parameter for anti-wrinkle treatment; the lower the value, the firmer the skin)
[0193] The number of fine lines in each test area of the subjects was counted using the Antera3D skin three-dimensional imaging system (mean ± SD, N = 31), and the results are shown in Table 13.
[0194] Table 13
[0195] area initial 2 weeks 4 weeks 8 weeks Control area ① 13.5 11.2 (−17.0%) 11.9 (−11.9%) 10.9 (−19.3%) Experimental Zone ① 14.6 10.8 (−26.0%) 10.3 (−29.5%) 9.3 (−33.6%) Control area ② 14.1 12.7 (−9.9%) 10.9 (−22.7%) 11.3 (−19.9%) Experimental Zone ② 13.9 10.2 (−26.6%) 9.7 (−30.2%) 9.1 (−34.5%)
[0196] As shown in Table 13, compared with the initial values, there were no significant differences in the number of fine lines in control areas ① and ② after 2 and 4 weeks of use, with a significant difference only appearing after 8 weeks of use (P < 0.05). However, compared with the initial values, the number of fine lines in experimental areas ① and ② were significantly different after 2, 4, and 8 weeks of use (P < 0.01). Furthermore, compared with the corresponding control areas, the number of fine lines in each experimental area was also significantly different after 2, 4, and 8 weeks of use (2 weeks P < 0.05, 4 weeks P < 0.05, 8 weeks P < 0.05). In summary, the recombinant collagen fragment exhibits a superior anti-wrinkle effect compared to the core functional area fragment of collagen.
[0197] 9) Average width of fine lines (mm, a key parameter for wrinkle resistance; the smaller the value, the narrower the fine lines)
[0198] The average width of fine lines in each test area of the subjects was measured and statistically analyzed using the Antera3D skin three-dimensional imaging system (mean ± SD, N = 31), and the results are shown in Table 14.
[0199] Table 14
[0200] area initial 2 weeks 4 weeks 8 weeks Control area ① 0.6678 0.7018(+5.1%) 0.6781(+1.5%) 0.6916(+3.6%) Experimental Zone ① 0.6547 0.6402(−2.2%) 0.6048(−7.6%) 0.6165(−5.8%) Control area ② 0.6191 0.6529(+5.5%) 0.6286(+1.5%) 0.6437(+4.0%) Experimental Zone ② 0.6227 0.6112(−1.8%) 0.6042(−3.0%) 0.6015(−3.4%)
[0201] As shown in Table 14, compared with control area ①, the average width of fine lines in test area ① showed significant differences after 2, 4, and 8 weeks of use (P < 0.05 at 2 weeks, P < 0.05 at 4 weeks, and P < 0.05 at 8 weeks); compared with control area ②, the average width of fine lines in test area ② also showed significant differences after 2, 4, and 8 weeks of use (P < 0.05 at 2 weeks, P < 0.05 at 4 weeks, and P < 0.05 at 8 weeks). This indicates that recombinant collagen fragments exhibit superior anti-wrinkle effects compared to simple collagen core functional area fragments.
[0202] 10) Average depth of fine lines (mm, a key parameter for anti-wrinkle treatment; the smaller the value, the shallower the fine lines)
[0203] The mean depth of fine lines in each test area of the subjects was measured and statistically analyzed using the Antera3D skin three-dimensional imaging system (mean ± SD, N = 31), and the results are shown in Table 15.
[0204] Table 15
[0205] area initial 2 weeks 4 weeks 8 weeks Control area ① 0.0160 0.0166 (+3.8%) 0.0154 (−3.8%) 0.0149 (−6.9%) Experimental Zone ① 0.0159 0.0144 (−9.4%) 0.0148 (−6.9%) 0.0145 (−8.8%) Control area ② 0.0173 0.0169 (−2.3%) 0.0164 (−5.2%) 0.0156 (−9.8%) Experimental Zone ② 0.0169 0.0156 (−7.6%) 0.0151 (−10.7%) 0.0141 (−16.6%)
[0206] As shown in Table 15, compared with the initial values, there were no significant differences in the average depth of fine lines in control areas ① and ② after 2, 4, and 8 weeks of use. However, compared with the initial values, there was a significant difference in the average depth of fine lines in test area ① after 2 weeks of use (P < 0.05), but no significant difference in the average depth of fine lines in the test area after 4 and 8 weeks of use; similarly, there was no significant difference in the average depth of fine lines in test area ② after 2 weeks of use, but a significant difference in the average depth of fine lines in test area ② after 4 and 8 weeks of use (P < 0.05).
[0207] Based on four indicators—firmness, roughness, fine line count, and average fine line depth—it can be seen that both recombinant collagen fragments have a definite wrinkle-reducing effect, with ESC0013 showing better efficacy.
[0208] 11) Safety evaluation
[0209] According to the skin adverse reaction grading standard for "Human Trial Safety Assessment" as specified in the 2015 edition of the "Cosmetic Safety Technical Specifications," 0 out of 31 subjects experienced skin adverse reactions (no redness, swelling, stinging, burning, itching, etc.) during the use of the recombinant collagen fragments ESC0012 and ESC0013. The transdermal administration demonstrates a high degree of safety.
Claims
1. A recombinant collagen fragment, characterized in that, It includes a collagen core functional region fragment and a chaperone tag fused to the N-terminus of the collagen core functional region fragment, the amino acid sequence of which is shown in SEQ ID No.
1.
2. The recombinant collagen protein fragment of claim 1, wherein, The amino acid sequence of the collagen core functional region fragment is shown in SEQ ID No. 2 or SEQ ID No.
9.
3. The recombinant collagen protein fragment of claim 1, wherein, The amino acid sequence is shown in SEQ ID No. 3 or SEQ ID No.
10.
4. The gene encoding the recombinant collagen fragment as described in any one of claims 1-3.
5. A nucleic acid construct, characterized in that, It contains the encoding gene as described in claim 4.
6. A recombinant expression vector, characterized in that, It contains the nucleic acid construct as described in claim 5.
7. A genetically modified engineered bacterium, characterized in that, It contains the encoding gene as described in claim 4.
8. The preparation process of the recombinant collagen fragment as described in any one of claims 1-3, characterized in that, Includes the following steps: S1. The genetically modified engineered bacteria described in claim 7 are inoculated into a culture medium and induced to ferment. S2. Collect and break the fermentation cells to obtain the whole cell lysate. Centrifuge to obtain the supernatant. Separate and purify the recombinant collagen fragment from the supernatant.
9. The preparation process according to claim 8, characterized in that, In step S2, the supernatant is subjected to Ni-NTA affinity chromatography and ion exchange chromatography in sequence to obtain a chromatographic solution. The chromatographic solution is then concentrated by ultrafiltration, filtered through a 0.22 μm membrane for sterilization, and dried to obtain the recombinant collagen fragment.
10. The use of the recombinant collagen fragment as described in any one of claims 1-3 in the preparation of topical skin care products.
